Get started
Author

Ismahène Benzaïd

Observed names: I. Benzaid, I. Benzaid*, I. Benzaïd, ISMAHENE BENZAID, Ismahene Benzaid, Ismahène Benzaid
Observed institutions: Lyon 1 Université, Inserm, University of Eastern Finland, Université de Lyon, Moffitt Cancer Center, Hôpital Edouard Herriot
ORCID: 0000-0002-0903-9054
Observed ORCIDs: 0000-0002-0903-9054, 0000-0001-9935-4236
OpenAlex ID: A5084458929
Bisphosphonates in cancer therapy
2007 · Verena Stresing, Florence Daubiné, et al. · Cancer Letters · 197
An immunoproteomic approach to characterize the CAR interactome and signalosome
2019 · Maria C. Ramello, Ismahène Benzaïd, et al. · Science Signaling · 157
High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity In Vivo
2011 · Ismahène Benzaïd, Hannu Mönkkönen, et al. · Cancer Research · 157
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase
2010 · Verena Stresing, Pierrick G. Fournier, et al. · Bone · 90
γδ-Enriched CAR-T cell therapy for bone metastatic castrate-resistant prostate cancer
2023 · Jeremy S. Frieling, Leticia Tordesillas, et al. · Science Advances · 72
PDF
Bisphosphonates in preclinical bone oncology
2010 · Philippe Clézardin, Ismahène Benzaïd, et al. · Bone · 52
In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2012 · Ismahène Benzaïd, Hannu Mönkkönen, et al. · Clinical Cancer Research · 51
Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells
2014 · S. Arkko, H.P. Zlatev, et al. · Cancer Letters · 9
Nitrogen-containing bisphosphonates and human γδ T cells
2010 · Ismahène Benzaid, Philippe Clézardin · IBMS BoneKEy · 5
Zoledronate-Induced IPP/ApppI (Phosphoantigen) Accumulation in Human Breast Cancer Cells Correlates with Vγ9VΔ2 T Cell-Mediated Cancer Cell Death In Vitro and In Vivo
2010 · Ismahene Benzaid, Hannu Mönkkönen, et al. · Bone · 4
1074 POSTER Effects of Zoledronic Acid and Denosumab on Human Vy9V62 T-cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells
2011 · I. Benzaïd, H. Mönkkönen, et al. · European Journal of Cancer · 2
Abstract 5281: Development of a panel of breast cancer patient-derived xenograft models (PDX) with estrogen independence and/or acquired resistance to endocrine treatment
2020 · Marc Hillairet de Boisferon, Ismahene Benzaid, et al. · Cancer Research · 1
Abstract 1706: An integrate comprehensive in vitro and in vivo strategies for antibody drug conjugate development
2026 · Ismahène Benzaid, Peggy Provent, et al. · Cancer Research
Abstract 6700: A fully integrated set of in vitro and in vivo tools for utilization of micro-organisms as new therapeutic weapons against cancer
2026 · Guillaume Serin, Lucie Demontoux, et al. · Cancer Research
Abstract 3916: Breast cancer brain metastasis development induced by intracarotid injection of MDA-MB 231 human breast cancer cells in mice
2025 · Romain Roth Dit Bettoni, Nicolas Hoffmann, et al. · Cancer Research
209 (PB197): Novel tumor microenvironment ameliorator E7130 shows substantial combination efficacy with enzalutamide in a preclinical model of castration-resistant prostate cancer.
2024 · T. Abe, K. Ito, et al. · European Journal of Cancer
Abstract 2826: Examples of translational preclinical models to mimic cancer drug resistance
2024 · Marc Hillairet de Boisferon, Nicolas Hoffmann, et al. · Cancer Research
Doublet and Triplet Combinations of Eribulin, Fulvestrant, and Palbociclib in Preclinical Breast Cancer Models
2023 · ISMAHENE BENZAID, MARC HILLAIRET DE BOISFERON, et al. · Anticancer Research
PDF
Supplementary Figure 3 from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
Supplementary Figure Legend from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
PDF
Supplementary Figure 2 from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
PDF
Supplementary Figure 1 from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
Data from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
Data from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
Supplementary Figure Legend from In Vivo Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Trigger Vγ9Vδ2 T-cell Antitumor Cytotoxicity through ICAM-1 Engagement
2023 · Ismahène Benzaïd, Hannu Mönkkönen, et al.
Works count: 37
Citation count: 797
H-index: 8
I10-index: 7
Year
Topic
Type